BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, Sanyal AJ, Kowdley KV, Neuschwander-Tetri BA, Brunt EM. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology. 2012;56:1311-1318. [PMID: 22532269 DOI: 10.1002/hep.25805] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
Number Citing Articles
1 Gaggini M, Carli F, Gastaldelli A. The color of fat and its central role in the development and progression of metabolic diseases. Horm Mol Biol Clin Investig 2017;31:/j/hmbci. [PMID: 28942436 DOI: 10.1515/hmbci-2017-0060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
2 Zang S, Chen J, Song Y, Bai L, Chen J, Chi X, He F, Sheng H, Wang J, Xie S, Xie W, Yang Y, Zhang J, Zheng M, Zou Z, Wang B, Shi J; Chinese NAFLD Clinical Research Network (CNAFLD CRN). Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. Adv Ther 2018;35:218-31. [PMID: 29411270 DOI: 10.1007/s12325-018-0670-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
3 Ozturk Y, Soylu OB. Fatty liver in childhood. World J Hepatol 2014;6:33-40. [PMID: 24653792 DOI: 10.4254/wjh.v6.i1.33] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
4 Haus JM, Solomon TP, Kelly KR, Fealy CE, Kullman EL, Scelsi AR, Lu L, Pagadala MR, McCullough AJ, Flask CA. Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2013;98:E1181-E1188. [PMID: 23616151 DOI: 10.1210/jc.2013-1229] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
5 Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G, Stimac D, Vlahovic-Palcevski V, Orlic L. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther 2015;9:4835-45. [PMID: 26316717 DOI: 10.2147/DDDT.S64877] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
6 Abshagen K, Mense L, Fischer F, Liebig M, Schaeper U, Navarro G, Glass Ä, Frank M, Klöting N, Vollmar B. Repin1 deficiency in liver tissue alleviates NAFLD progression in mice. J Adv Res 2019;16:99-111. [PMID: 30899593 DOI: 10.1016/j.jare.2018.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Delli Bovi AP, Marciano F, Mandato C, Siano MA, Savoia M, Vajro P. Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. Front Med (Lausanne) 2021;8:595371. [PMID: 33718398 DOI: 10.3389/fmed.2021.595371] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
8 Arata M, Nakajima J, Nishimata S, Nagata T, Kawashima H. Nonalcoholic steatohepatitis and insulin resistance in children. World J Diabetes 2014;5:917-23. [PMID: 25512797 DOI: 10.4239/wjd.v5.i6.917] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
9 Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol 2013;10:676-85. [PMID: 24126564 DOI: 10.1038/nrgastro.2013.193] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
10 Komolafe O, Buzzetti E, Linden A, Best LM, Madden AM, Roberts D, Chase TJ, Fritche D, Freeman SC, Cooper NJ, Sutton AJ, Milne EJ, Wright K, Pavlov CS, Davidson BR, Tsochatzis E, Gurusamy KS. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database Syst Rev 2021;7:CD013157. [PMID: 34280304 DOI: 10.1002/14651858.CD013157.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Koh H, Kim S, Kim MJ, Kim HG, Shin HJ, Lee MJ. Hepatic fat quantification magnetic resonance for monitoring treatment response in pediatric nonalcoholic steatohepatitis. World J Gastroenterol 2015;21:9741-8. [PMID: 26361421 DOI: 10.3748/wjg.v21.i33.9741] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
12 Zhou X, Ren L, Yu Z, Huang X, Li Y, Wang C. The antipsychotics sulpiride induces fatty liver in rats via phosphorylation of insulin receptor substrate-1 at Serine 307-mediated adipose tissue insulin resistance. Toxicol Appl Pharmacol. 2018;345:66-74. [PMID: 29551354 DOI: 10.1016/j.taap.2018.02.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
13 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
14 Spahis S, Alvarez F, Dubois J, Ahmed N, Peretti N, Levy E. Plasma fatty acid composition in French-Canadian children with non-alcoholic fatty liver disease: Effect of n-3 PUFA supplementation. Prostaglandins Leukot Essent Fatty Acids. 2015;99:25-34. [PMID: 26066299 DOI: 10.1016/j.plefa.2015.04.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
15 Rachakonda V, Gabbert C, Raina A, Li H, Malik S, DeLany JP, Behari J. Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines. Alcohol Clin Exp Res. 2014;38:2712-2721. [PMID: 25421508 DOI: 10.1111/acer.12558] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
16 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
17 Cha E, Paul S, Braxter BJ, Umpierrez G, Faulkner MS. Dietary Behaviors and Glucose Metabolism in Young Adults at Risk for Type 2 Diabetes. Diabetes Educ 2018;44:158-67. [PMID: 29495910 DOI: 10.1177/0145721718756057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Wang J, Gao H, Ke D, Zuo G, Yang Y, Yamahara J, Li Y. Improvement of liquid fructose-induced adipose tissue insulin resistance by ginger treatment in rats is associated with suppression of adipose macrophage-related proinflammatory cytokines. Evid Based Complement Alternat Med 2013;2013:590376. [PMID: 23533500 DOI: 10.1155/2013/590376] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
19 Popov VB, Lim JK. Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. J Clin Transl Hepatol. 2015;3:230-238. [PMID: 26623270 DOI: 10.14218/jcth.2015.00019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 4.2] [Reference Citation Analysis]
20 Matsubayashi Y, Yoshida A, Suganami H, Ishiguro H, Yamamoto M, Fujihara K, Kodama S, Tanaka S, Kaku K, Sone H. Role of fatty liver in the association between obesity and reduced hepatic insulin clearance. Diabetes Metab 2018;44:135-42. [PMID: 29395810 DOI: 10.1016/j.diabet.2017.12.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
21 Labarca G, Cruz R, Jorquera J. Continuous Positive Airway Pressure in Patients With Obstructive Sleep Apnea and Non-Alcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. J Clin Sleep Med. 2018;14:133-139. [PMID: 29151428 DOI: 10.5664/jcsm.6900] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
22 Cernea S, Cahn A, Raz I. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Rev Clin Pharmacol. 2017;10:535-547. [PMID: 28276774 DOI: 10.1080/17512433.2017.1300059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
23 Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62:S65-S75. [PMID: 25920092 DOI: 10.1016/j.jhep.2015.02.041] [Cited by in Crossref: 170] [Cited by in F6Publishing: 141] [Article Influence: 34.0] [Reference Citation Analysis]
24 Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:637-653. [PMID: 25194181 DOI: 10.1016/j.bpg.2014.07.008] [Cited by in Crossref: 189] [Cited by in F6Publishing: 147] [Article Influence: 27.0] [Reference Citation Analysis]
25 Neuschwander-tetri BA. Future Treatments of NASH. Curr Hepatology Rep 2016;15:125-33. [DOI: 10.1007/s11901-016-0300-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
26 Hassan K, Bhalla V, El Regal ME, A-Kader HH. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol. 2014;20:12082-12101. [PMID: 25232245 DOI: 10.3748/wjg.v20.i34.12082] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 81] [Article Influence: 17.3] [Reference Citation Analysis]
27 Khalili M, King WC, Kleiner DE, Jain MK, Chung RT, Sulkowski M, Lisker-melman M, Wong DK, Ghany M, Sanyal A, Sterling RK. Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. Clinical Infectious Diseases 2020. [DOI: 10.1093/cid/ciaa1303] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
28 Aihara Y, Yoshiji H, Noguchi R, Kaji K, Namisaki T, Shirai Y, Douhara A, Moriya K, Kawaratani H, Fukui H. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model: DRI attenuates the progression of NASH. Hepatol Res 2013;43:1241-50. [DOI: 10.1111/hepr.12081] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
29 Søndergaard E, Espinosa De Ycaza AE, Morgan-Bathke M, Jensen MD. How to Measure Adipose Tissue Insulin Sensitivity. J Clin Endocrinol Metab 2017;102:1193-9. [PMID: 28323973 DOI: 10.1210/jc.2017-00047] [Cited by in Crossref: 64] [Cited by in F6Publishing: 46] [Article Influence: 16.0] [Reference Citation Analysis]
30 Shen T, Xu B, Lei T, Chen L, Zhang C, Ni Z. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway. Exp Ther Med 2018;16:3121-8. [PMID: 30214535 DOI: 10.3892/etm.2018.6554] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
31 Tilg H, Adolph TE, Moschen AR. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology. 2021;73:833-842. [PMID: 32780879 DOI: 10.1002/hep.31518] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 35.0] [Reference Citation Analysis]
32 Patel SS, Siddiqui MS. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. Drugs. 2019;79:75-84. [PMID: 30588564 DOI: 10.1007/s40265-018-1040-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
33 Reyes-garcía R, Rozas-moreno P, Llamoza-torres CJ, Mezquita-raya P. Hígado graso no alcohólico y diabetes. Medicina Clínica 2017;148:33-8. [DOI: 10.1016/j.medcli.2016.08.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Ghadieh HE, Muturi HT, Russo L, Marino CC, Ghanem SS, Khuder SS, Hanna JC, Jash S, Puri V, Heinrich G, Gatto-Weis C, Lee KY, Najjar SM. Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis. Hepatol Commun 2018;2:35-47. [PMID: 29404511 DOI: 10.1002/hep4.1117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
35 Moncada R, Rodríguez A, Becerril S, Méndez-Giménez L, Valentí V, Ramírez B, Cienfuegos JA, Fernández S, Catalán V, Gómez-Ambrosi J, Frühbeck G. Sleeve Gastrectomy Decreases Body Weight, Whole-Body Adiposity, and Blood Pressure Even in Aged Diet-Induced Obese Rats. Obes Surg 2016;26:1549-58. [PMID: 26439733 DOI: 10.1007/s11695-015-1919-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
36 Takashima S, Ikejima K, Arai K, Yokokawa J, Kon K, Yamashina S, Watanabe S. Glycine prevents metabolic steatohepatitis in diabetic KK-A y mice through modulation of hepatic innate immunity. American Journal of Physiology-Gastrointestinal and Liver Physiology 2016;311:G1105-13. [DOI: 10.1152/ajpgi.00465.2015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
37 Liu Y, You J, Xu W, Zhai T, Du C, Chen Y, Han F. Gynura procumbens aqueous extract alleviates nonalcoholic steatohepatitis through CFLAR-JNK pathway in vivo and in vitro. Chinese Herbal Medicines 2019;11:369-78. [DOI: 10.1016/j.chmed.2019.09.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
38 Ganesh S, Rustgi VK. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016;20:351-64. [PMID: 27063274 DOI: 10.1016/j.cld.2015.10.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
39 Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc 2015;90:1233-46. [PMID: 26219858 DOI: 10.1016/j.mayocp.2015.06.013] [Cited by in Crossref: 127] [Cited by in F6Publishing: 102] [Article Influence: 21.2] [Reference Citation Analysis]
40 Kim CW, Addy C, Kusunoki J, Anderson NN, Deja S, Fu X, Burgess SC, Li C, Ruddy M, Chakravarthy M, Previs S, Milstein S, Fitzgerald K, Kelley DE, Horton JD. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metab 2017;26:394-406.e6. [PMID: 28768177 DOI: 10.1016/j.cmet.2017.07.009] [Cited by in Crossref: 106] [Cited by in F6Publishing: 99] [Article Influence: 35.3] [Reference Citation Analysis]
41 Gaggini M, Carli F, Rosso C, Younes R, D'Aurizio R, Bugianesi E, Gastaldelli A. Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease. Int J Mol Sci 2019;20:E6333. [PMID: 31888144 DOI: 10.3390/ijms20246333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
42 Li Y, Wang J, Gu T, Yamahara J, Li Y. Oleanolic acid supplement attenuates liquid fructose-induced adipose tissue insulin resistance through the insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt signaling pathway in rats. Toxicology and Applied Pharmacology 2014;277:155-63. [DOI: 10.1016/j.taap.2014.03.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
43 Pearlman M, Loomba R. State of the art: treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2014;30:223-237. [PMID: 24717764 DOI: 10.1097/mog.0000000000000060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
44 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021;18:73-91. [PMID: 33268887 DOI: 10.1038/s41423-020-00579-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
45 Zen Y, Kondou H, Nakazawa A, Tanikawa K, Hasegawa Y, Bessho K, Imagawa K, Ishige T, Inui A, Suzuki M, Kasahara M, Yamamoto K, Yoshioka T, Kage M, Hayashi H. Proposal of a liver histology-based scoring system for bile salt export pump deficiency. Hepatol Res 2020;50:754-62. [PMID: 32073700 DOI: 10.1111/hepr.13494] [Reference Citation Analysis]
46 Ampuero J, Romero-Gomez M. Stratification of patients in NASH clinical trials: A pitfall for trial success. JHEP Rep 2020;2:100148. [PMID: 32954243 DOI: 10.1016/j.jhepr.2020.100148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
47 Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, Oren R; FLORA Group. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2085-2091.e1. [PMID: 24815326 DOI: 10.1016/j.cgh.2014.04.038] [Cited by in Crossref: 150] [Cited by in F6Publishing: 130] [Article Influence: 21.4] [Reference Citation Analysis]
48 Gastaldelli A, Gaggini M, Daniele G, Ciociaro D, Cersosimo E, Tripathy D, Triplitt C, Fox P, Musi N, DeFronzo R, Iozzo P. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Hepatology. 2016;64:2028-2037. [PMID: 27639082 DOI: 10.1002/hep.28827] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 12.8] [Reference Citation Analysis]
49 Park HJ, Han JM, Kim HG, Choi MK, Lee JS, Lee HW, Son CG. Chunggan extract (CGX), methionine-and choline-deficient (MCD) diet-induced hepatosteatosis and oxidative stress in C57BL/6 mice. Hum Exp Toxicol 2013;32:1258-69. [PMID: 23970447 DOI: 10.1177/0960327113485253] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
50 Rodríguez A, Gena P, Méndez-Giménez L, Rosito A, Valentí V, Rotellar F, Sola I, Moncada R, Silva C, Svelto M, Salvador J, Calamita G, Frühbeck G. Reduced hepatic aquaporin-9 and glycerol permeability are related to insulin resistance in non-alcoholic fatty liver disease. Int J Obes (Lond) 2014;38:1213-20. [PMID: 24418844 DOI: 10.1038/ijo.2013.234] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
51 Karsdal MA, Henriksen K, Genovese F, Leeming DJ, Nielsen MJ, Riis BJ, Christiansen C, Byrjalsen I, Schuppan D. Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes. Diabetologia 2017;60:50-9. [DOI: 10.1007/s00125-016-4094-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
52 Bashir MR, Wolfson T, Gamst AC, Fowler KJ, Ohliger M, Shah SN, Alazraki A, Trout AT, Behling C, Allende DS, Loomba R, Sanyal A, Schwimmer J, Lavine JE, Shen W, Tonascia J, Van Natta ML, Mamidipalli A, Hooker J, Kowdley KV, Middleton MS, Sirlin CB; NASH Clinical Research Network (NASH CRN). Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease. J Magn Reson Imaging. 2019;49:1456-1466. [PMID: 30318834 DOI: 10.1002/jmri.26312] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
53 Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Circ Res 2020;126:679-704. [PMID: 32105577 DOI: 10.1161/CIRCRESAHA.119.316337] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 30.0] [Reference Citation Analysis]
54 Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39:328-348. [PMID: 29846945 DOI: 10.1002/med.21515] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]